Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Comprehensive RNA-Based Testing and Selective Next-Generation TKIs Are Reshaping ...

1 September 2026 · By · Wire by Fusion42

Published

1 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at onclive.com →

◆ Verified

Fusion42 · 1 September 2026 · Fusion42 review

Comprehensive RNA-based testing alongside selective next-generation tyrosine kinase inhibitors (TKIs) are improving detection and treatment sequencing for ROS1-positive non–small cell lung cancer (NSCLC), with enhanced efficacy especially in central nervous system metastases.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You must upgrade RNA and DNA testing methods in lung cancer diagnostics this week to capture actionable ROS1 fusions missed by DNA alone. New TKIs now extend survival and brain metastasis control, reshaping treatment choices for targeted therapy developers.

◆ Coverage

1 source · 1 Sep 2026

◆ Related on Wire

◆ Topics

Biotechros1nsclcrna-testingnext-gen-tkiscns-metastases